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Abstract
Background: Cervical cancer is the most frequent neoplasm among Kenyan women, with 4800 diagnoses and
2400 deaths per year. One reason is an extremely low rate of screening through pap smears, at 13.8% in 2014.
Knowing the costs of screening will help planners and policymakers design, implement, and scale programs.
Methods: We conducted HPV-based cervical cancer screening via self-collection in 12 communities in rural Migori
County, Kenya. Six communities were randomized to community health campaigns (CHCs), and six to screening at
government clinics. All HPV-positive women were referred for cryotherapy at Migori County Hospital. We prospectively
estimated direct costs from the health system perspective, using micro-costing methods. Cost data were extracted
from expenditure records, staff interviews, and time and motion logs. Total costs per woman screening included three
activities: outreach, HPV-based screening, and notification. Types of inputs include personnel, recurrent goods, capital
goods, and services. We costed potential changes to implementation for scaling.
Results: From January to September 2016, 2899 women were screened in CHCs and 2042 in clinics. Each CHC lasted
for 30 working days, 10 days each for outreach, screening, and notification. The mean cost per woman screened was
$25.00 for CHCs [median: $25.09; Range: $22.06-30.21] and $29.56 for clinics [$28.90; $25.27-37.08]. Clinics had higher
costs than CHCs for personnel ($14.27 vs. $11.26) and capital ($5.55 vs. $2.80). Screening costs were higher for clinics
at $21.84, compared to $17.48 for CHCs. In contrast, CHCs had higher outreach costs ($3.34 vs. $0.17). After modeling
a reduction in staffing, clinic per-screening costs ($25.69) were approximately equivalent to CHCs.
Conclusions: HPV-based cervical cancer screening through community health campaigns achieved lower costs per
woman screened, compared to screening at clinics. Periodic high-volume CHCs appear to be a viable low-cost strategy
for implementing cervical cancer screening.
Keywords: Cervical cancer screening, HPV testing, Micro-costing, Rural Kenya
Background
Introduction
Invasive cervical cancer is highly preventable through
organized screening programs. However, globally over
half a million women are diagnosed with the disease
each year [1]. Cervical cancer is the most common can-
cer among women in Sub-Saharan Africa [2]. Nine out
of 10 cervical cancer deaths occur in low-resource coun-
tries, with an 85% mortality rate in Sub-Saharan Africa
[3, 4]. While in developed countries a major decline in
cervical cancer incidence and mortality occurred after
the introduction of cytologic testing, many developing
countries still lack effective screening programs [5].
High cancer mortality rates in developing countries
may be due to inadequate health facilities and lack of
personnel [6–8]. Organized screening programs are rare,
and screening rates are low in developing countries,
where only 19% of women are screened for cervical
cancer as compared to 83% in the U.S. [9]. Simplified
screening strategies employing testing for high-risk
human papillomavirus (HPV), the causative agent in
most cervical cancers, have been shown to reduce
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mortality from cervical cancer when coupled with out-
patient treatment of precancerous lesions [5, 10, 11]. Pro-
grams implementing HPV testing in community-based
settings may address the infrastructure and personnel lim-
itations that prevent screening in some low-resource
settings.
In Kenya, cervical cancer is the most frequent cancer
among women, with about 4800 annual diagnoses and
over 2400 deaths per year [12]. HPV testing is recom-
mended by Kenya’s Ministry of Public Health and Sanita-
tion’s Division of Reproductive Health, but is not reliably
incorporated into most community or government pro-
grams [13]. Visual inspection with acetic acid-based
screening is available at some clinics in Kenya. Screening
rates are extremely low, at 13.8% nationwide and below
11% in rural areas in 2014 [14]. Even when screening is
available, uptake can remain poor, due to low levels of
knowledge of cervical cancer [15], and lack of awareness
of HPV screening and the risks of cervical cancer [16].
Very few women recognize that routine testing is the
primary way to prevent cervical cancer [17].
The community-based health fair is an important
strategy to help people in developing countries access
important preventive healthcare messaging and services.
Community health campaigns (CHCs) occur over a
short duration, delivering preventive health services at
high-volume close to residential areas. CHCs have been
effective in reducing maternal and neonatal mortality
[18–20], prevention of malaria [21], HIV testing and
delivery of antiretrovirals [22, 23], tuberculosis detection
[24], and increasing mental health care access [25]. A
multi-disease CHC in rural Kenya found increased
ART coverage and other health benefits with cost savings
[26, 27]. CHCs are part of a community-based healthcare
model, which has gained traction in recent years because
it can mobilize a large proportion of a community, and
may be less resource-intensive than receiving preventive
care at clinics.
In this study, we used costing data collected during a
cluster-randomized trial in rural Kenya comparing uptake
of HPV-based cervical cancer screening in community
health campaigns and government clinics to compare
the costs of the strategies. This is the first study to
estimate the costs of cervical cancer screening with a
community-based health campaign strategy, and
furthermore, compares the costs of two cervical cancer
screening interventions in Kenya. The cost estimations
will help inform future implementers on funding and re-
source needs for cervical cancer screening.
Study description
This study was conducted as part of a cluster-randomized
trial in 12 rural communities in Migori County in the
former Nyanza Province of western Kenya between
January and September 2016. Two-thirds of citizens of
Nyanza live on less than $1 per day, and the province has
the highest prevalence of HIV in the country. The target
population was women who were eligible for and would
benefit from cervical cancer screening per the Kenya
Ministry of Health Guidelines: 25 to 65 years old with an
intact uterus and cervix. Site selection was based on
census data, health facility information, mapping, and
demographic data [28]. Each community was a cluster of
villages or sub-locations within a defined administrative
boundary. The twelve communities were randomized in a
1:1 ratio using an allocation sequence generated by Stata
11 MP (StataCorp, TX). Six communities were random-
ized to a CHC intervention and six to HPV screening at
government clinics.1 Despite random assignment, women
in CHCs were slightly older and more likely to have been
screened for cervical cancer in the past [28]. Non-adjacent
communities with a population of 4500 to 9000, with at
least one health facility were identified. Both arms
included three phases for which costs are presented: out-
reach and mobilization (“Outreach”), HPV-based screen-
ing (“Screening”), and notification of results and standard
referral (“Notification”). Treatment services were equiva-
lent between the arms, and therefore not costed. More in-
formation on the details of the study design can be found
in the main outcomes paper, Huchko et al. 2017 [28].
Figure 1a and b summarize the workflows for each of
the three phases for CHC communities and clinic com-
munities, respectively. For CHC communities, each of
the three phases (Outreach, Screening, and Notification)
lasted two weeks. A subset of the CHC team conducted
outreach through stakeholder meetings, information
sessions, door-to-door mobilization, announcements
using a public-address system, and posters. During
screening, the entire CHC team traveled to different
areas of the CHC community every morning and set up
tents. The team then conducted a sequence of activities
dedicated to screening for each woman visiting the tents:
registration, group education, informed consent, and
self-collection of screening specimens using the
careHPV test kit. The lab technician then tested whether
the woman was HPV-positive using the careHPV™ test
system. After two weeks of screening activities, the CHC
team moved onto notification of results and standard re-
ferral, which again lasted two weeks. Program assistants
worked on using text messages and phone calls to notify
women of their results, and Community Health Volunteers
(CHVs) employed by the program conducted door-to-door
home visits to notify women of their status. HPV-positive
participants received referral to a treatment site located at
Migori County Hospital.
In contrast to CHCs, each of the three phases were con-
ducted concurrently at the six clinic communities for nine
months total. After an initial series of key stakeholder
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meetings and information sessions prior to launching
screening, one to two CHVs at each clinic conducted out-
reach through door-to-door mobilization and posters.
During screening, CHVs, with supervision from the pro-
gram coordinator and assistance from the data manager
and program administrator, conducted all the screening
activities at the clinic sites. They conducted group educa-
tion, acquired informed consent, and collected HPV
self-collection test kits. Notification also occurred
throughout the nine months of screening at each clinic
site. Since CHVs attended clinics fulltime and were in
charge of notifying women who decided to visit clinics to
receive test results, the CHVs were not involved with
home visit notification, in contrast to CHCs. Instead, a
team of program assistants would conduct home visits
(1-3 days per month for each clinic) to notify women of
their test results. The program assistants issued text mes-
sages and phone calls. HPV-positive women were referred
for treatment at Migori County Hospital. More detailed
information on the CHC and clinic community workflows
is in the Additional file 1.
Methods
Micro-costing procedures, a method of valuation in
health economics that involves the “direct enumeration
and costing of every input consumed in the treatment of
a particular patient” (Siegel et al. 1996), were applied to
quantify resources used for HPV testing in each arm
(clinic and CHC). Recommendations on economic
evaluations of health system interventions made by
Drummond and Jefferson (1996) and Weinstein et al.
(1996) guided our analyses [29, 30]. Direct costs were es-
timated from the health system perspective through a
prospective analysis. We conducted an economic
analysis of costs, where all inputs were costed, whether do-
nated or subsidized, and costs of labor or wage rates were
based on market wages and salaries. The micro-costing
method was a hybrid of top-down and bottom-up, depend-
ing on the cost-item and data collected. For most cost
items, we enumerated the item (based on numbers used for
the community), multiplied the number by the cost of each
item whether purchased or donated, and estimated unit
(per-screening) costs from the sum of costs.
A
B
Fig. 1 a Personnel team and activities of CHCs across 3 phases: outreach, screening, and notification. b Personnel team and activities of Clinics
across 3 phases: outreach, screening, and notification
Shen et al. BMC Health Services Research  (2018) 18:378 Page 3 of 10
Capital goods cost estimation was based on total costs
from expenditure records. Capital goods are tangible
assets including vehicle for transportation, tents for
CHCs, and the careHPV ™ test system, which is a rapid
batch diagnostic test designed for HPV-testing in
low-resources settings (Qiagen, Cost Gaithersburg,
Maryland). Costs of capital items were amortized on a
straight-line basis over five years assuming no salvage
value. For the vehicle and tents, the costs were allocated
evenly across the 6 CHC communities. For the careHPV
™ test system, costs were allocated on a per-screening
basis in each of the 12 communities. Communities with
more screenings had higher costs allocated for the test
system. More information on capital goods costing is in
the Additional file 2.
Personnel costs were estimated based on salary re-
cords. Costs of personnel for CHCs were based on the
monthly salaries and the amount of time spent on each
phase of the CHC. Since all phases for CHCs lasted two
weeks, the personnel cost for a phase was the person-
nel’s estimated salary for two weeks. Since clinic
personnel worked on all six clinic communities concur-
rently, the total per-clinic personnel costs were
estimated based on the number of women screened at
each clinic, i.e. the proportion of women screened in
each clinic community over the total number of women
screened at clinics. More information on personnel cost-
ing is in the Additional file 2.
The primary data used to measure the costs of each
intervention activity were expenditure records,
interviews, time and motion logs, direct counts made by
the costing lead, market rates, salary records, and
estimations based on government data (MOH/NAS-
COP) for facility space costs. Tables 1 and 2 of the
(Additional file 3: Table S1 and Additional file 4:
Table S2) show in-depth information on the data sources
for quantity, price, and percent allocation towards
program or non-program activities at CHC and clinic
communities. The cost data was collected manually and
subsequently electronically recorded on Excel workbooks.
The cost items were classified under five input types:
personnel, recurrent goods, services, capital goods, and
facility overhead. The number of units and price of
each input was recorded. Number of input units and
price were converted into a total economic cost. All
costs reported are in 2016 U.S. dollars, converted
from Kenyan shillings at an exchange rate of 95
Kenyan shillings per U.S. dollar [31].
Once total economic cost of each item was calculated,
each cost item was further allocated to program and
non-program purposes. For example, time spent on
administering pre- and post-screening surveys was a re-
search activity, and was omitted from program cost
estimates. To arrive at a unit cost (per completed
screening), total economic cost of each item that was
designated for program purposes was divided by the
number of women screened at each community. The
Additional file 2 provides further detail on how each cat-
egory of cost (personnel, capital goods, facility, recurrent
goods, services) was recorded and estimated.
Using the unit-cost estimations, the micro-costing data
was then aggregated to estimate total costs per woman
screened at a CHC and clinic community. In the costing
analyses, we compared costs across the six CHC com-
munities, and conducted a similar comparison across
the six clinic communities. The costs per woman
screened at each of the 12 communities were broken
down by type of costing input (personnel, facility,
services, recurrent goods, capital), and phase (outreach,
screening, and notification). We did not include cost of
treatment because the treatment model was identical be-
tween the CHC and clinic arms.
Sensitivity analysis
A series of sensitivity analyses were conducted to assess
whether costs per screening estimated are sensitive to
changes in implementation. First, cost estimates for CHCs
were conducted under two alternate transportation
Table 1 Cost estimations, in 2016 USD, by phase and cost type,
per woman screened with self-collected HPV in community
health campaigns in six communities in 2016
Community Health Campaign Community #
1 2 3 4 5 6
Outreach
Capital Goods 0.51 0.92 0.67 0.72 0.64 0.53
Personnel 2.00 3.18 2.32 2.26 1.66 1.18
Recurrent Goods 0.01 0.02 0.02 0.56 0.24 0.25
Services 0.32 0.51 0.35 0.40 0.43 1.01
Outreach Subtotal 2.84 4.63 3.36 3.94 2.97 2.97
Screening
Capital Goods 1.18 1.82 1.38 1.47 1.59 1.15
Personnel 5.09 9.00 7.72 6.40 4.91 4.80
Recurrent Goods 8.11 8.82 8.42 8.70 8.21 8.09
Services 2.36 2.31 1.16 1.48 1.30 1.46
Screening Subtotal 16.74 21.95 18.69 18.05 16.02 15.51
Notification
Capital Goods 0.51 0.92 0.67 0.72 0.64 0.53
Personnel 3.47 2.17 3.47 3.28 3.66 2.78
Recurrent Goods 0.08 0.02 0.08 0.07 0.04 0.05
Services 0.33 0.51 0.12 0.13 0.48 0.22
Notification Subtotal 4.40 3.63 4.34 4.21 4.82 3.58
Women screened 602 337 461 430 483 586
Cost per screening 23.98 30.21 26.39 26.21 23.81 22.06
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scenarios to purchasing a program vehicle: (1) issuing
travel reimbursements, or (2) renting a vehicle. For two of
the six CHCs, travel vouchers were issued because a ve-
hicle was not purchased at the time of the CHC. Travel
reimbursement rates for these two CHCs were therefore
used to approximate cost per kilometer of travel.2 A
rented vehicle costs 4000 KES per day, or 42 USD a day.
In the second sensitivity analysis, we explored a sce-
nario where clinic personnel are used more efficiently,
and therefore measure the costs of reducing the number
of personnel dedicated to clinic screening. The research
team, based on observation and experience, believed that
each clinic could have hired another CHV who was
dedicated to conducting home visits for the notification
phase, rather than using program assistants. During the
study, clinics each had five program assistants conduct
home visits 1-3 times a month, which may have driven
up personnel costs for notification at clinics. The team
also believed that the program coordinator and data
manager could have reduced their time spent on clinic
activities, and delegated more responsibility to a
program assistant, who would manage operations and
data collection. The maximum number of clinics a pro-
gram assistant could have managed was two clinics.
Therefore, in the sensitivity analysis, a program assistant
would dedicate full time to monitoring screening and
notification at two clinics, where he or she would over-
see the progress of the CHV and make appointments
with certain patients who need more attention. The pro-
gram coordinator would commit 5% time to each clinic,
and lab technicians would dedicate time to each clinic
based on the number of women screened (same as be-
fore, average 10% time across clinics). Each clinic would
therefore only have four team members: CHV, program
assistant, program coordinator, and lab technician. The
personnel ratio per clinic would reduce from 2 to 1.65.
Finally, we also implemented cost regressions to
estimate the fixed cost for the screening program and the
marginal costs of each screening. We estimated total cer-
vical cancer screening costs, one from each community,
and regressed total costs on numbers of women screened
in each community. Each cost regression has 6 observa-
tions, one from each CHC and clinic community.
Results
Between January and September 2016, 2899 women
were screened at the six CHC communities and 2042 at
the six clinic communities. In Tables 1 and 2, the
site-by-site cost breakdown per woman screened is pre-
sented. The mean cost per woman screened was $25.00
for CHCs and $29.56 for clinics. The mean number of
women screened was 482 per CHC and 340 per clinic.3
Differences between CHCs and clinics
Figure 2a and b depict cost breakdowns of CHC and
clinic community costs, by cost type and phase, respect-
ively. Personnel costs were higher for clinics ($14.27 per
screening) compared to CHCs ($11.26 per screening).
Capital costs were also higher for clinics ($5.55)
compared to CHCs ($2.68), due to the need for clinics
to pay for renting space at facilities.4 Services were al-
most equivalent ($2.48 for CHCs and $2.29 for clinics).
Recurrent goods were the only input type that was
slightly higher for CHCs, at $8.59 per screening
compared to $7.45 for clinics; this reflects additional
transportation costs associated with executing a CHC
(e.g. fuel costs and transport reimbursements).
When comparing CHCs and clinics across activities,
per-screening costs were higher for CHCs only in out-
reach ($3.34 vs $0.17 at clinics), whereas per-screening
costs were higher for clinics for screening ($17.59 for
CHCs and $21.88 for clinics) and notification ($4.18 for
CHCs and $7.51 for clinics). CHCs had higher costs
for outreach because they conducted more intensive
outreach activities than clinics, including door-to-door
mobilization, public address systems, and meetings with
chief elders. A larger team of personnel was involved with
CHC outreach activities. At clinics, the only outreach con-
ducted was door-to-door mobilization by CHVs. During
door-to-door mobilization at clinics, CHVs visited homes
Table 2 Cost estimations, in 2016 USD, by phase and cost type,
per woman screened with self-collected HPV in clinics, in six
communities in 2016
Clinic Community #
1 2 3 4 5 6
Outreach
Personnel 0.10 0.19 0.19 0.14 0.12 0.20
Recurrent Goods 0.01 0.02 0.02 0.01 0.01 0.02
Outreach Subtotal 0.11 0.21 0.21 0.15 0.13 0.22
Screening
Capital Goods 1.89 2.20 1.33 1.66 2.09 3.57
Facility 10.78 2.49 3.32 2.17 0.41 2.09
Personnel 8.10 6.72 6.63 6.63 6.75 6.83
Recurrent Goods 7.24 7.73 6.43 6.86 7.98 9.70
Services 1.70 2.04 2.28 1.84 1.55 2.82
Screening Subtotal 29.73 21.17 19.99 19.17 18.78 25.01
Notification and Standard Referral
Personnel 5.82 8.00 7.96 6.85 6.31 8.29
Services 1.42 0.26 0.00 0.09 0.05 0.00
Notification Subtotal 7.24 8.26 7.96 6.94 6.35 8.30
# women screened 326 502 338 450 269 157
Cost per screening 37.08 29.64 28.16 26.26 25.27 33.53
Notes: Community #2 had a total of 3 separate clinics; Community #3 had a
total of 2 separate clinics; and Community #4 had a total of 2 separate clinics
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one-by-one and provided information on cervical cancer
screening conducted at clinics. Costs of mobilization were
low for clinics because daily compensation of CHVs is
lower than wage rates for personnel staff. In clinic
communities, CHVs also put up posters with further in-
formation about screening. The outreach activities at
CHCs generated higher numbers of women screened at
CHCs compared to clinics (483 vs. 340) in a shorter
period of time (10 days vs. nine months).
Figure 3 shows further breakdown of personnel costs
by cadre. While CHCs had higher costs for data
management and other miscellaneous personnel costs
(e.g. driver, security, tent setup team), clinics had higher
personnel costs associated with hired program assistants
(type 1 was involved with monitoring screening at the
clinics, and type 2 were involved with home visits during
notification).
Differences across sites, for CHCs and clinics
Variation in costs per woman screened across CHCs can
largely be attributed to differences in numbers of women
screened at each CHC. For example, personnel team size
A B
Fig. 2 a and b CHC and clinic average cost per screening estimates, color coded by cost type and phase
Fig. 3 Bar graph of CHC and clinic personnel cost estimate breakdowns, by cadre
Shen et al. BMC Health Services Research  (2018) 18:378 Page 6 of 10
and compensation rates do not change much across
CHCs, but per-screening personnel costs for the screen-
ing phase among CHCs range from $4.80 to $9.00. Simi-
larly, for capital goods, the cost of capital goods such as
the careHPV test system, tablet, and pipettes, do not
change for different CHC communities. Per-screening
capital goods costs for the screening phase therefore
vary because of differences in numbers of women
screened at each community. Variation in recurrent
goods ($8.09 to $8.82 per screening during the screening
phase) occurred across communities because of differ-
ence in fuel costs and amount of supplies required for
screening. Variation in services offered for notification
(texts, calls, and home visits) occurred because of differ-
ences in notification options selected at each CHC.
Variation in cost per screening for clinics was primar-
ily due to differences in costs of facility space. For most
clinics, facility rent was not entirely allocated for cervical
cancer screening, because other health services such as
HIV testing were conducted in the same space. One
clinic, however, had considerably higher facility costs be-
cause 100% of a clinic room was allocated to CCSP
screening. Clinic personnel designated to screening
activities shifted across the six clinics, which is why there
was slight variation in clinic-level personnel costs. The
team of personnel involved with notification did not
change across clinics, and therefore, personnel costs for
notification did not vary.
For capital goods, all six communities used the central
careHPV Test System and shared two motorbikes.
Similar to personnel, clinic-level costs of capital goods
were estimated based on proportion of women screened
at each clinic, and therefore did not vary much across
the clinics.
Sensitivity analyses
In the sensitivity analysis in which transportation strat-
egies were varied, the average cost per screening for
CHCs under both transportation scenarios declined very
slightly, at $23.12 per screening with a range of $20.53
to $27.51 for the transport reimbursement scenario, and
at $24.98 per screening with a range of $21.68 to $30.42
for the rented vehicle scenario. The CHC cost per
screening estimates are therefore not very sensitive to
changes in transportation type used for the program.
In the second sensitivity analysis, personnel costs at
clinics were estimated with an adjustment to team
structure. During the program, a total of 11 individ-
uals comprised clinic personnel: eight working on
screening, and nine working on notification, with a
personnel ratio of about two per clinic. Additionally,
each clinic had one CHV working on both screening
(trained to help women self-sample using HPV
self-test kits) and notification.
Table 3 shows the results of the sensitivity analysis.
Average cost per screening reduced to $25.69 for clinics,
with a range of $20.57 to $32.12. The results measured a
change in personnel efficiency. The average cost per
screening from the sensitivity analysis was similar to
per-screening costs of CHCs, differing by only 69 cents.
Finally, we conducted two cost regressions for the six
CHCs and six clinic communities to empirically estimate
the program fixed cost per community screened and the
marginal cost of a screening. For CHCs, the regression
results showed an intercept of $5368.24 representing
fixed costs, and marginal costs of $13.89, representing
variable costs. For clinic communities, the regression re-
sults showed an intercept of $982.27 representing fixed
costs, and marginal costs of $26.68, representing variable
costs. CHCs had higher fixed costs than clinics, and
clinics had higher marginal costs than CHCs.
Discussion
This study determined and compared the costs of HPV
based cervical cancer screening for women in Kenya
through two distinct strategies: HPV self-sampling
offered in brief community health campaigns (CHC)
designed to rapidly screen women, or in government
clinics. The study found that the CHC was less expen-
sive ($25.00 per screening) than HPV based-screening at
government clinics ($29.56 per screening), at a differ-
ence of $4.56 per screening. The findings can help
inform the planning and design of future cervical cancer
screening programs implemented in similar low- and
middle-income regions with high-burden of disease.
Table 3 Sensitivity analysis with modeled costs per screening
based on a reduction in personnel responsible for screening
and notification at clinics
Clinic Community # Observed Clinic
Costs (from Table 2)
Per-screening costs at
each clinic after personnel
adjustment
1 $37.08 $30.93
2 $29.64 $26.62
3 $28.16 $24.89
4 $26.26 $22.27
5 $25.27 $20.57
6 $33.53 $32.12
Average cost per
screening
$29.56 $25.69
Notes: Estimated per-screening costs at each of the 6 control clinics based on
a reduction in number of personnel involved with screening and notification.
Each clinic is designated 1 CHV dedicated to both screening and notification.
One program assistant dedicates 100% of their time to monitoring screening
and notification at 2 clinics. The program coordinator will commit 5% time to
each clinic, and lab technicians dedicate time to each clinic based on the
number of women screened (same as before, average 10% time). Each clinic
will therefore only have 4 team members: CHV, HE, program coordinator, and
lab technician. The personnel ratio per clinic will reduce from 2 to 1.65. No
other changes were made to estimated costs
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Etiologies of increased costs throughout the cervical
cancer prevention cascade can help identify areas to
target and develop more cost-efficient strategies for
future evaluation.
Costs per screening differed between CHCs and clinics
for two main reasons. First, CHCs may have had lower
per-screening costs than clinics because of higher
numbers of women screened on average in CHC com-
munities. CHCs were likely more successful at recruiting
women for cervical cancer screening because of more in-
tensive outreach and mobilization efforts. Outreach and
mobilization for CHCs involved a larger team than
clinics, and included several more high-visibility promo-
tion activities including involvement of community el-
ders and public-address systems. Since CHCs screening
activities were placed in prominent locations within each
community, the excitement surrounding a community
health “event” may have also encouraged more women
to get screened. The more intensive recruitment efforts
dedicated to CHCs brings up the question of whether
more intensive recruitment for government clinics
would have led to more screenings in control communi-
ties. The CHC was mobile, switched locations each day
of the 10-day campaign, and was more integrated with
communities. Thus, it is difficult to attribute the higher
numbers of women screened to simply more outreach,
or the combination of outreach and CHC integration
and visibility within communities. Future studies could
incorporate equivalent outreach efforts for government
health clinics to identify the effect of a screening site
that is mobile and integrated within the community.
The second possible reason for higher costs per
screening in clinics is that there was too much staffing
allocated for clinics during the study, especially with the
lower numbers of women screened. Given the possibility
that personnel size for implementation at clinics was lar-
ger than necessary, we simulated costs under the sce-
nario of a smaller team dedicated to clinic screening
activities (18% decline in personnel) in the sensitivity
analysis. For this hypothetical scenario, average costs per
screening were approximately the same as average costs
per screening at CHCs ($25.69 versus $25.00). It is diffi-
cult to conclude that all other activities at the clinic, in-
cluding the number of women who visited the clinic for
screening, would have been exactly equivalent under this
hypothetical personnel structure in the sensitivity ana-
lysis. Future studies could explore effectiveness of clinic
screening with fewer personnel involved with screening
and notification, and the cost models are helpful ad-
juncts to discussions with program planners.
This was the first study to measure costs of
self-sampling in Kenya using cost data captured directly
from program implementation, including not just the
screening, but the essential mobilization and notification
components. Furthermore, this study was the first to
compare the costs of two different implementation strat-
egies for cervical cancer screening in Kenya, a low in-
come, and high-burden country. Prior to this study,
cervical cancer costs in Kenya were only measured using
a predictive model [32] and through a time and motion
study of integrating cervical cancer screening at one
HIV clinic [33]. The costs of implementation were com-
prehensively estimated through collection of program
data, which can be used as reference for future cervical
cancer screening programs in Kenya.
This analysis had several limitations. The first is the
low number of communities where CHCs were imple-
mented; Six CHC communities were compared with six
control communities. Including more communities in
the study may have allowed for more robust compari-
sons in costs per screening. The second, an efficiency
curve occurred for CHCs that may have caused the first
campaigns to be more expensive. The final consideration
is whether CHCs can feasibly be scaled-up as a nation-
wide program, and whether government or donor sup-
port could fund regular CHCs.
Conclusion
This study compared six short-term cervical cancer
screening community health campaigns with six com-
munities offering cervical cancer screening at clinics in
rural Kenya. Results show that mean costs per woman
screened at the six CHC communities were slightly
lower than mean costs per woman screened at the six
clinic communities ($25.00 compared to $29.56). In our
experience, cervical cancer screening at community
health campaigns increased screening coverage and low-
ered per-women screening costs as a result. Future cer-
vical cancer screening programs should consider the
option to integrate screening activities at community
health campaigns, with an emphasis on increasing the
efficacy of outreach to increase screening numbers and
improve efficiency.
Endnotes
1The 6 CHC communities were Oyani, Ongito, Nyarongi,
Nyamanga, Obware, and Ageng’a. The 6 clinic communi-
ties were Diruma, God Jope, Got Kachola, Nyamasare,
Ondong, and Winjo. There were 6 communities where
HPV screening was conducted through clinics, but a total
of 10 clinics.
2We assume that each liter of gasoline translates to 96
Kenyan shillings.
3The costing table for each of the 10 clinics is in the
Additional file 5: Table S3.
4In this figure, facility costs incurred at clinics were
labeled as a capital cost, since rent represents payment
towards a capital investment.
Shen et al. BMC Health Services Research  (2018) 18:378 Page 8 of 10
Additional files
Additional file 1: Detailed information on CHC and Clinic Workflow:
Includes in-depth information on how screening was set-up and facili-
tated by the implementation team and providers at both CHCs and
clinics. (DOCX 17 kb)
Additional file 2: Further detail on cost estimation methods of each
cost type (personnel, capital, facility, recurrent goods, and services):
Includes in-depth information on the sources, data collection method,
and cost estimation method of each of the major cost category types.
Includes how personnel costs were allocated across sites, and how capital
costs were amortized. (DOCX 16 kb)
Additional file 3: Table S1. Major cost items for each cost type for
CHCs, with data source information on quantity, unit and total costs, and
% allocation across purposes. (DOCX 19 kb)
Additional file 4: Table S2. Major cost items for each cost type for
Clinics, with data source information on quantity, unit and total costs,
and % allocation across purposes. (DOCX 18 kb)
Additional file 5: Table S3. Cost estimations per woman screened at all
10 clinics, from January to September 2016. Includes cost estimations of
the three phases of implementation: outreach and mobilization,
screening, and notification and standard referral. (DOCX 22 kb)
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